View : 25 Download: 5

Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products

Title
Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products
Authors
Lee, SoyoungKim, Han WoolKim, Kyung-Hyo
Ewha Authors
김경효김한울
SCOPUS Author ID
김경효scopus; 김한울scopus
Issue Date
2016
Journal Title
JOURNAL OF KOREAN MEDICAL SCIENCE
ISSN
1011-8934JCR Link1598-6357JCR Link
Citation
vol. 31, no. 12, pp. 1937 - 1942
Keywords
AntibodyHepatitis A VirusHepatitis B VirusIntravenous Immunoglobulin
Publisher
KOREAN ACAD MEDICAL SCIENCES
Indexed
SCI; SCIE; SCOPUS; KCI WOS scopus
Abstract
The worldwide seroprevalence of hepatitis A virus (HAV) and hepatitis B virus (HBV) has changed over the last two decades, indicating a declining incidence of HAV and HBV infections. Therefore, vaccinations against HAV and HBV are recommended for unimmunized people before traveling to an endemic area. Unfortunately, primary antibody deficiency (PAD) patients can only obtain humoral immunity through intravenous immunoglobulin G (IVIG) replacement and not from vaccination because of a defect in antibody production. However, few studies have analyzed the titers of antibodies against HAV or HBV in IVIG products. In this study, the titers of anti-HAV and anti-HBs antibodies were measured in nineteen lots of IVIG products from five manufacturers from three countries (A, B from Korea; C, D from Japan; and E from the USA), and trough titers in plasma were estimated. Concentrations of anti-HAV antibody ranged from 1,888-8,927 mIU/mL and estimated trough titers exceeded the minimal protective value in all evaluated vertical bar V vertical bar G products. Concentrations of anti-HBs antibody ranged from 438-965 mIU/mL in products A and B and were 157, 123, and 1,945 mIU/mL in products C, D, and E, respectively. Estimated trough titers in products A, B, and E exceeded the minimal protective value but those in products C and D did not reach this threshold. These data demonstrated that available IVIG products generally provide sufficient antibodies against HAV and HBV to protect patients with PAD, although the trough concentrations of anti-HBs antibody in two IVIG products did not reach the minimum protective value.
DOI
10.3346/jkms.2016.31.12.1937
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
Antibodies against hepatitis a and hepatitis b virus in intravenous immunoglobulin products.pdf(394.03 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE